Features

ISPE Global Pharmaceutical Regulatory Summit Speaker Panel
Features
Distant Assessments, Audits, & Regulatory Guidance
The ISPE Global Pharmaceutical Regulatory Summit, held virtually on 28 April 2021, brought together 11 regulators from different parts of the world to discuss how their approaches to GMP inspections have adapted to the COVID-19 pandemic.
Figure 1: PQLI integration over the product life cycle.
Features
PQLI®: Advancing Innovation & Regulation
A unique aspect of the pharmaceutical industry is the pairing of innovation and regulation. For nearly two decades, ISPE’s Product Quality Lifecycle Initiative (PQLI®) has worked at the nexus of pharmaceutical manufacturing technology and regulation to bring forward solutions that help advance new...
Submission and review process diagram
Features
ICH Quality Guidelines: Present Initiatives & ISPE Involvement
In its 30-year history, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has covered a wide range of topics to generate quality, safety, efficacy, and multidisciplinary harmonized guidelines. As science advances, issued guidelines are...
ISPE’s Regulatory Affairs function
Features
ISPE’s Regulatory Affairs function
ISPE’s Regulatory Affairs function plays a vital role in the Society, which is to build effective relationships with regulators and agencies globally and ensure all members have access to the latest regulatory developments and expectations. These activities are driven by the collective efforts of...
A Vision for ICH Q12: Current Experience, Future Perspectives
Features
A Vision for ICH Q12: Current Experience, Future Perspectives
Management of global postapproval chemistry, manufacturing, and controls (CMC) changes is a growing challenge for industry with many issues. ICH Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management) is a transformative document shaping global regulatory...
Continuous Manufacturing as a Tool for Accelerated Development
Features
Continuous Manufacturing as a Tool for Accelerated Development
Continuous manufacturing (CM) offers one way the pharmaceutical industry can accelerate development of the drug product control strategy to ensure a robust and reliable supply of medicine to the clinic and/or market. This article explores the promise of continuous manufacturing in enhancing...
Regulatory Aspects of Global Acceptance of Continuous Manufacturing
Features
Regulatory Aspects of Global Acceptance of Continuous Manufacturing
Application of continuous manufacturing (CM) in the pharmaceutical industry is gaining momentum. Most of the current experience is based on oral solid dosage (OSD) projects but in the future continuous manufacturing should not be limited to these dosage forms. In this article, the regulatory...
Continuous Manufacturing Good Practice Guide Is Planned
Features
Continuous Manufacturing Good Practice Guide Is Planned
The ISPE OSD Community of Practice Continuous Manufacturing Subcommittee is planning a Good Practice Guide to capture information developed over several years by the team to establish equipment requirements, identify opportunities for harmonization and flexible integration, and suggest where...
Navigating the Life Cycle for Cell & Gene Therapies
Features
Navigating the Life Cycle for Cell & Gene Therapies
Cell and gene therapies are complex. As more therapies come to market in the hope of bringing advanced treatments and cures to rare, orphan, and difficult-to-treat diseases, designing quality standards for these personalized medicines is equally as complex.European Commission. EudraLex, Volume 4:...
Opportunities in Continuous Manufacturing of Large Molecules
Features
Opportunities in Continuous Manufacturing of Large Molecules
Continuous manufacturing has attracted significant interest over the past decade for small molecules formulated as drug products. The case for adopting continuous manufacturing platforms for manufacturing biologics (i.e., large proteins or biologic products such as vaccines) would, in principle, be...
Effect of Industry 4.0 enablers on the product life cycle.
Features
Data Science for Pharma 4.0™: Drug Development, & Production—Part 2
This second of a two-part series explores digital transformation and digitalization in the biopharmaceutical industry with information about how data science enables digitalization along the product life cycle. (Part 1 was published in the March-April 2021 issue of Pharmaceutical...
Functional interface overview.
Features
Cloud Computing Implications for Manufacturing Execution Systems
Cloud computing can be described as networked access and utilization of configurable computing resources such as data and information storage, processing capabilities, applications, and other services on computerized systems provided and/or maintained by a remote organization. As life sciences...
Happy 30th Anniversary to the GAMP® Community of Practice!
Features
Happy 30th Anniversary to the GAMP® Community of Practice!
In 2021, the ISPE GAMP® Community of Practice (CoP) is celebrating 30 years of promoting industry good practice for computerized systems and encouraging technical innovation and progress, while protecting patient safety, product quality, and data integrity.
Best Practices for Deploying Real-World Evidence Solutions
Features
Best Practices for Deploying Real-World Evidence Solutions
Real-world evidence (RWE) is clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD) relating to patient health status and the healthcare delivery.US Food and Drug Administration. “Use of Real-World Evidence to...
IT Services: Applying Good IT Practice & Automation
Features
IT Services: Applying Good IT Practice & Automation
This article focuses on pragmatic quality- and risk-based approaches to IT infrastructure. It covers recommendations made by a US FDA/industry team linked to the US FDA Center for Devices and Radiological Health (CDRH) Case for Quality initiativeUS Food and Drug Administration Center for Devices...
ISPE Pharma 4.0™ SIG & Its Working Groups
Features
ISPE Pharma 4.0™ SIG & Its Working Groups
The ISPE Pharma 4.0™ Special Interest Group (SIG) launched in 2015 to provide a road map for new challenges of digitalization, Industry 4.0, and the smart factory. The Special Interest Group addresses how pharmaceutical industry stakeholders, including regulatory authorities, can achieve benefits...
The holistic supply chain
Features
Holistic Control Strategy: From ICH Quality Guidelines to Pharma 4.0™
The fourth Industrial Revolution (also known as Industry 4.0) is the era of smart machines, storage systems, and production plants that can autonomously exchange information, trigger actions, and control operations free of any human intervention. To ensure future success in the delivery of...
Effect of Indutry 4.0 enablers on the manufacturing process chain. Upper arrow: Conventional approach. Lower arrow: Perceived extended process chain using IIoT enablers.
Features
Data Science for Pharma 4.0™, Drug Development, & Production—Part 1
Digital transformation and digitalization are on the agenda for all organizations in the biopharmaceutical industry. But what are the main enablers of intelligent manufacturing? We hypothesize that data science–derived manufacturing process and product understanding is the main driver of...
Empathy phase elements identified in the workshop
Features
"How to Pitch and Shape a Pharma 4.0™ Project” Workshop
During the ISPE Pharma 4.0™ Virtual Conference, the Management Communication working group of the ISPE Pharma 4.0™ Special Interest Group (SIG) held a workshop to support ISPE members in pitching, shaping, and presenting a Pharma 4.0™ project/program to company management.
The History & Future of Validation
Features
The History & Future of Validation
Across every industry today, digitalization is driving the use and value of data to disrupt traditional business models and ways of working. In pharmaceuticals, the promises of Industry 4.0 are expected, and needed, to finally modernize the legacy approaches that have evolved since the 1970s....
Figure 1: Integrating quality risk management and data flow management during product design.
Features
Breaking with Tradition: Laying the Foundation for Validation 4.0
A fundamental GMP requirement is that processes, systems, and methods used to produce medicines and treatments are validated, meaning their fitness for a purpose is demonstrated. If Industry 4.0 is to succeed in the pharma space as Pharma 4.0™, we need new paradigms for validation across the value...
Data and analytics architecture at Eli Lilly and Company used with permission from D. Sternasty, Eli Lilly and Company).
Features
2020 ISPE Pharma 4.0™ Virtual Conference Highlights
Through this difficult time of the COVID-19 pandemic, ISPE has remained active. At the 2020 ISPE Pharma 4.0™ Virtual Conference, 17–18 November, 174 attendees gathered online to discuss and learn about the progress of the pharma-specific industry 4.0 approach, Pharma 4.0™ (now a registered...
Figure 4: The ISPE Quality Metrics Initiative/APQ timeline. Key: FDASIA, Food and Drug Safety and Innovation Act; FRN, Federal Register notice.
Features
ISPE’s APQ Program & Guides Advance Pharmaceutical Quality
ISPE has announced the launch of its Advancing Pharmaceutical Quality (APQ) Program with the publication of the ISPE APQ Guide: Corrective Action and Preventive Action (CAPA) System, a guide dedicated to the topic of CAPA. This article describes how the APQ Program has been built and summarizes the...
Figure 1: Examples of graphs generated from PEEM-DB.
Features
A New Pharmaceutical Equipment Exposure Measurement Database
This article describes the Pharmaceutical Equipment Exposure Measurement Database (PEEM-DB), which was launched in July 2019 by the ISPE Japan Affiliate for its members. PEEM-DB is offered as a tool for rationally advancing optimal containment equipment settings by collecting exposure measurement...
Creating Effective Standard Operating Procedures
Features
Creating Effective Standard Operating Procedures
Personnel management is the most challenging variable in maintaining current Good Manufacturing Practice (cGMP) across the life cycle of drug manufacture, safety, and supply. A standard operating procedure (SOP) outlines agreed-upon instructions for personnel training and instructions for...
Model-Informed Drug Development Addresses COVID-19 Challenges
Features
Model-Informed Drug Development Addresses COVID-19 Challenges
Drug developers know that the odds of anyone compound demonstrating safety and efficacy for a disease and its affected populations are low. How can drug developers improve these odds and increase the efficiency and effectiveness of drug development? One useful tool is model-informed drug...
Women in Pharma®:Empowering Women as Industry Leaders
Features
Women in Pharma®: Empowering Women as Industry Leaders
Women in Pharma® is a place where women and men—especially those new to the industry—can access a network of mentors, role models, and educational resources to support their professional success. The widespread global interest and participation in this initiative and its events have shown that...
Joydeep Ganguly
Features
Industry Leaders: Focused on the Mission
Joydeep Ganguly, who is currently Senior Vice President, Corporate Operations, at Gilead Sciences, Inc., places a premium on working for a mission-oriented company. “If you choose the right company with the right ethos and a deep, tangible commitment to the patients, the mission is not just...
Figure 1: CNN model training process and validation results for a lyophilized vial AVI system.
Features
Vision Inspection Using Machine Learning/Artificial Intelligence
Pharmaceutical companies rely on automated vision inspection (AVI) systems to help ensure product safety. Although these systems overcome challenges associated with manual inspection, they can be hindered by limitations in their programming—if the system is programmed to consider every variation in...
Plenary session at the 2019 ISPE Europe Biotechnology Conference in Brussels in September 2019.
Features
2019 ISPE Europe Biotechnology Conference: Industry Transformations
As biopharmaceuticals have become a major part of the pharmaceutical industry, we have witnessed significant transformations in product development, strategy, technology, and operations. This ongoing transformational process was the main theme of the fourth annual ISPE Europe Biotechnology...
Current State of Oligonucleotide Therapeutics
Features
Current State of Oligonucleotide Therapeutics
Oligonucleotides are a relatively new class of drugs, composed of natural and synthetic nucleotides, which primarily include small interfering RNA (siRNA), micro RNA (miRNA), and antisense oligonucleotide (ASO). These molecules achieve therapeutic effects through RNA interference, degradation, or...
Figure 1: Cell therapy life cycles.
Features
Flexible Facility Design for Multiple Cell Therapy Processes
In many critical ways, the design of facilities for multiple cell therapy processes is unlike the design of conventional pharmaceutical facilities. This article surveys several of the key issues to consider when designing facilities capable of manufacturing multiple cell therapies, including...
Figure 1: A global supply scenario with cross-country and cross-cultural interfaces
Features
Operational Risk Management in Global Supply Scenarios
The current regulatory framework in the pharmaceutical industry places pressure on marketing authorization holders (MAHs) to demonstrate quality oversight, and a systematic risk management process is a prerequisite for avoiding compliance and productivity pitfalls. This article focuses on options...
Cell & Gene Therapy Facility Design Using Simulations
Features
Cell & Gene Therapy Facility Design Using Simulations
Designing new facilities for cell and gene therapy manufacturing is a challenging task given the many uncertainties in this industry sector, including varying potential demand for any given new therapy, evolving platforms and technology, questions about equipment reliability, learning curves for...
Validation of Clinical Trial–Related Systems in Smaller Enterprises
Features
Validation of Clinical Trial–Related Systems in Smaller Enterprises
Existing risk-based approaches to computerized system compliance and validation as outlined in GAMP® 5International Society for Pharmaceutical Engineering. GAMP® 5 Guide: A Risk-Based Approach to Compliant GxP Computerized Systems. North Bethesda, MD: International Society for Pharmaceutical...
ISPE France Affiliate: Long-Time Affiliate Continues to Shine
Features
ISPE France Affiliate: Long-Time Affiliate Continues to Shine
The ISPE France Affiliate is fortunate in many ways. The pharmaceutical industry in France is world class, employing close to 100,000 people and generating €55.9 billion in annual revenue.LEEM. “French Pharmaceutical Industry—Key Data 2019.” Accessed 9 July 2020....
Technology Trends: The Transition to Digitalization
Features
Technology Trends: The Transition to Digitalization
In the pharmaceutical industry, digitalization involves developing and implementing digital technologies at all levels of pharmaceutical operations. The aim is to transform the industry by capturing, analyzing, and using vast amounts of data collected from a wide range of sources to support...
Reporting categories for changes in the drug substance (DS) and drug product (DP) process and analytical methods per FDA guidance [
Features
Case Study: Facilitating Efficient Life-Cycle Management via ICH Q12
The latest ICH guideline, ICH Q12,International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. “ICH Harmonised Guideline: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Q12. Final Version.” 20 November 2019....
Achieving Vertical & Horizontal Integration in Pharma 4.0™
Features
Achieving Vertical & Horizontal Integration in Pharma 4.0™
Recent projects on serialization and track and trace help illustrate the concepts of vertical and horizontal integration. With vertical integration, the unique product identification information (serial number, lot, etc.) used by sensors and printers on the packaging lines is made accessible to the...
Regulatory Panel Session: Explores Key Aseptic Topics
Features
Regulatory Panel Session: Explores Key Aseptic Topics
The 2020 ISPE Aseptic Conference was capped off on Tuesday, 3 March, by the Interactive Regulatory Panel session, which has been a popular feature of the conference during its 29 years. The session featured a panel of seven US FDA regulators who addressed a long and varied list of questions about...
Tracking the Journey of Barrier Technology
Features
2020 ISPE Barrier Survey: Tracking the Journey of Barrier Technology
For over two decades, the ISPE Barrier Isolator Survey has gathered meaningful data on the applications of barrier technology and been a resource for the fill-finish pharmaceutical industry community. This article provides context for the latest survey, the first in several years, and presents its...
Pam Cheng
Features
Industry Leaders: Mission-Driven Leadership
Pam Cheng is Executive Vice President, Global Operations & Information Technology, at AstraZeneca, a United Kingdom–headquartered pharmaceutical company with more than 60,000 employees. In this role, she combines her expertise as an engineer with business savvy and seeks opportunities to lead her...
Wearable Devices & Biometrics Improving Efficiency in GxP Operations
Features
Wearable Devices & Biometrics Improving Efficiency in GxP Operations
As the old saying goes, “Time is money.” In today’s industrialized world, this adage is profoundly true. Manufacturers can no longer afford to overlook operational excellence. A new production philosophy called “Lean manufacturing” has been developed to save as much time as possible during...
Regulators Address Innovations & Harmonization
Features
Regulators Address Innovations & Harmonization
At the 2019 ISPE Global Pharmaceutical Regulatory Summit, regulators updated attendees on approaches to industry innovations and the ongoing work on harmonization and reliance around the world.
Update from the ISPE Regulatory Steering Council
Features
Update from the ISPE Regulatory Steering Council
Virtually every ISPE member has at least one story to tell about how health authority inspections or the review and approval of regulatory applications have affected their efforts to supply critically needed medications to patients globally. Although these stories may emphasize the considerable...
Article
Features
ISPE Comments to the Annex 2 PIC/S Draft Revision
Annex 2 is the Good Manufacturing Practices (GMP) document by the Pharmaceutical Inspection Co-operation Scheme (PIC/S) addressing manufacture of biological medicinal substances and products for human use. This article shares information about Annex 2 and ISPE’s submitted comments to the draft...
ICH Q12: A Transformational Product Life-Cycle Management Guideline
Features
ICH Q12: A Transformational Product Life-Cycle Management Guideline
On 20 November 2019, the ICH Assembly endorsed the Q12 guideline, “Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management,” at its biannual meeting in Singapore. This transformational guideline has a wide scope of applicability across pharmaceutical drug substances...
A Gamp® Approach to Robotic Process Automation
Features
A GAMP® Approach to Robotic Process Automation
This article introduces the concept of robotic process automation (RPA) and discusses how the technology may be used within a GAMP® framework to support both non-GxP and GxP processes.
Sustainability & the Life Sciences Industry: A Global Introduction cover
Features
Sustainability & the Life Sciences Industry: A Global Introduction
In this issue of Pharmaceutical Engineering®, we address an array of sustainability topics. This article surveys topics that will likely have a significant global impact on the way we conduct our business over the coming decade. We trace some history of sustainability in the life sciences industry...
Company A energy audit summary (annual carbon savings by utility category).
Features
Two Real-World Experiences in Global Sustainability
The article appraises the real-world experiences of two pharmaceutical companies approaching the rollout of energy- and water-reduction programs to selected facilities around the world. It is the result of more than two years of collaboration between the company corporate teams, individual site...
Figure 2: Energy Venn diagram (per I.S. 399) and filter dryer example.
Features
Implementation of a Formal Energy-Efficient Design Process
Sustainability is a key principle for pharmaceutical companies in 2020. However, translating corporate goals into meaningful improvements can be a challenge, particularly when competing factors such as complex technical requirements or ambitious project schedules are involved.
Figure 1: Sources of pharmaceuticals in the environment. Adapted from reference
Features
Industry Perspective: Bioremediation of Pharmaceuticals
Medical treatments and pharmaceuticals are indispensable in improving quality of life. In recent years, however, pharmaceutical compounds have become a significant group of environmental pollutants, shown to pose risks to human health and have adverse environmental effects.
Introducing Industry Leaders
Features
Introducing Industry Leader Profile Articles
With the start of the new year, Pharmaceutical Engineering® is launching a new series of profiles of industry leaders. This ongoing series will look at the lives and careers of individuals who are changing the face of the pharmaceutical industry.
Industry Leaders: An Advocate for Quality - Ranjana B. Pathak
Features
Industry Leaders: An Advocate for Quality
Ranjana B. Pathak, BSc (Hons), MBA, DHA, has spent nearly 40 years in the pharmaceutical industry. Currently the President and Global Head of Quality, Medical Affairs, and Pharmacovigilance at Cipla Ltd. in Mumbai, India, Pathak’s long tenure has afforded her an informed perspective on the past,...
Industry Leaders: Bringing Pharma 4.0™ Into the World - Christian Wölbeling
Features
Industry Leaders: Bringing Pharma 4.0™ Into the World
Every important cause needs its champion. Champions have a vision of how things should be, and a passion to reach their goals. They are committed and determined to achieve positive results, are willing to do the heavy lifting, and will take consistent and massive action until results are achieved.
Biotech Industry’s Quest for Optimized Manufacturing Facility Design
Features
Biotech Industry’s Quest for Optimized Manufacturing Facility Design
Since the early 1990s, when the “upstart” biotech industry realized that its future success would be heavily influenced by the ability to manufacture multiple products within the same facility,Hill, D., and M. Beatrice. “Biotechnology Facility Requirements, Part 1, Facility and Systems Design.”...
Figure 2: ISPE Pharma 4.0™ operating model
Features
Applying Holistic Control Strategy in Pharma 4.0™
Applying emerging technologies can lead to more robust and flexible manufacturing processes that in turn can help the pharmaceutical industry respond to drug shortages, reduce interruptions in production and delivery of medicines, ensure consistent clinical performance of products, and achieve...
Figure 2: Steps in a holistic cleanroom concept.
Features
A Holistic Cleanroom Concept: Higher Quality & Greater Flexibility
As the pharmaceutical industry balances demands for small-batch and blockbuster products and encounters new regulations, there is a need for efficient and safe production technologies that can meet stringent quality and safety requirements for the aseptic filling of drugs. Looking forward,...
Article of the Year Logo
Features
Continuous Manufacturing in Biotech Processes
Article of the Year 2018 Winner: The winner of the 2018 Roger F. Sherwood Article of the Year award is “Continuous Manufacturing in Biotech Processes: Challenges for Implementation” by Robert Dream, PE, CPIP; Christoph Herwig, PhD; and Emilie...
Industrializing New Platforms
Features
Industrializing New Platforms
Moving platforms from development to the delivery of more biopharmaceuticals to more patients is reality, not just a concept, for Moderna, Inc. Juan Andres, the company’s Chief Technical Operations and Quality Officer, presented on “mRNA Medicines—Industrializing a New Platform” at the 2019 ISPE...
Why ISPE GAMP® Supports the FDA CDRH: Case for Quality Program
Features
Why ISPE GAMP® Supports the FDA CDRH: Case for Quality Program
The US FDA Center for Devices and Radiological Health (CDRH) Case for Quality program promotes a risk-based, product quality–focused, and patient-centric approach to computerized systems. This approach encourages critical thinking based on product and process knowledge and quality risk management...
Practical Regulatory and Industry Panel
Features
Practical Regulatory & Industry Issues
Presenters and a panel of FDA regulators and industry experts discussed key regulatory and industry issues during the closing plenary of the 2019 ISPE Biopharmaceutical Manufacturing Conference.
Eric S. Langer
Features
Biopharma Growth Trends: More Innovation on the Way
Innovation has been and continues to be a driver for the strides being made in biopharma development and manufacturing, noted Eric S. Langer, President and Managing Partner, BioPlan Associates, Inc., who addressed “Innovation in Transformative...
Cell and Gene Therapies and Their GMP Requirements
Features
Cell and Gene Therapies & Their GMP Requirements
Cell and gene therapies are the latest revolution in medicine manufacturing. Unlike small molecules or traditional biotech products, these therapies introduce cells and genes into a patient to treat the underlying cause of a disease—they are living medicines.
2019 ISPE Biopharmaceutical Manufacturing Conference
Features
The Next Wave in Biopharma Manufacturing
Innovations in production methods and technologies that enable a competitive and sustainable biopharmaceutical product supply were the focus of presentations at the 2019 ISPE Biopharmaceutical Manufacturing Conference in Boston, Massachusetts, 18–20 June. Future directions for the biopharma...
Risk Management in Single-Use Technology
Features
Risk Management in Single-Use Technology
Risk management is pervasive throughout the biopharmaceutical industry. It is an important factor during the implementation of new equipment or procedures into an operation. Likewise, risk management is also key when assessing the impact of changes. When doing a root cause analysis, evaluation of...
Patient-Centric Specification: Regulatory and Industry Progress
Features
Patient-Centric Specification: Regulatory & Pharma Industry Progress
On 5 June 2018, a plenary session entitled ”Patient-Centric Specification” (PCS) was held at the 2018 ISPE Quality Manufacturing Conference in Arlington, Virginia. More than 160 professionals from worldwide innovator and generic pharmaceutical companies, academia, and regulatory agencies attended....
Digital representation of a chemical API process
Features
The Digital Twin: Creating Efficiencies in a Virtual World
The Pharma 4.0™ Special Interest Group is focusing on key technologies that will modernize pharmaceutical manufacturing and facilitate digital transformation. These technologies include digital twins, augmented reality, artificial intelligence, big data and analytics, mobiles, cloud, advanced...
Application of SOC 2+ Process to Assessment of GxP Suppliers of Services
Features
Application of SOC 2+ Process to Assessment of GxP Suppliers of Services
To facilitate the assessment and mitigation of compliance risks associated with a third-party service organization, its services, and the systems used to provide the services, this article proposes adopting an approach from the financial sector that, with a little modification, could be used to...
Improving Pharmaceutical Connections with Patients cover
Features
Improving Pharmaceutical Connections with Patients
Being on the cutting edge of drug development is the goal of most pharmaceutical companies, but a new drug won’t work if the patient doesn’t take it. It’s a vexing problem that developers of healthcare technologies hope to address.
Holistic Control Strategies for Continuous Manufacturing
Features
Holistic Control Strategies for Continuous Manufacturing
Innovative technologies such as continuous manufacturing (CM) bring speed, efficiency, and agility to pharmaceutical manufacturing together with enhanced process robustness and assurance of product quality. During CM, material is simultaneously charged and discharged into process unit operations....
Serialization model
Features
Ten Frequently Asked Questions about Serialization
To meet the EU serialization deadline on 9 February 2019, pharmaceutical companies and their contractors have had to reorganize their manufacturing lines and logistics to ensure compliance with the EU’s Falsified Medicines Directive (FMD) of 2011 and the EU Commission Delegated Regulation 2016/161...
Continuous Manufacturing cover
Features
Regulatory Progress - Global Advancement of Continuous Manufacturing for Pharma
Continuous manufacturing (CM) is an advancement in pharmaceutical manufacturing technology that provides high assurance of product quality as well as enough flexibility and agility in production to respond to market demands. The decision to invest in CM can be challenging for a company given the...
Biopharma Growth & Regulatory Perspectives
Features
Biopharma Growth & Regulatory Perspectives
The 2018 ISPE Biopharmaceutical Manufacturing Conference on 10–12 December in Huntington Beach, California, provided information about future-oriented developments in the burgeoning area of biopharmaceutical manufacturing—and also shared insights into the achievements that are already underway....
Identifying Global Themes in Clinical Study Participants’
Features
Identifying Global Themes in Clinical Study Participants’
This article examines patient preferences in one facet of clinical research: the experience related to the use of investigational medicinal products (IMPs). As patients have become more involved and informed in their healthcare choices, the “voice of the patient” has been increasingly incorporated...
Generic Drugs Banner
Features
The Philippines: Biosimilars—Opportunities & Challenges
It is the duty of the government to improve access to safe, effective, and quality medicines for its constituents. Various approaches are taken by different countries to achieve this; for the Philippines, the approach is through the active promotion of...
Generic Drugs Banner
Features
Japan: Generics Leading Expansion
In Japan, off-patented drugs are not always converted to generic drugs but may remain on the drug list as off-patented-drug products. These are customarily classified into three groups: patented drugs; off-patented drugs (“long-listed drugs”); and...
Generic Drugs Banner
Features
China: Pursuing Quality for Generics & Biosimilars
Over the past several years, Chinese regulatory authorities have signaled an increased awareness of the need to improve quality standards for both generic and biosimilar drugs. In 2015, the China Food and Drug Administration (CFDA) (now NMPA, National...
Generic Drugs Banner
Features
India: From Generics to Biosimilars
India has become a major producer of generics drugs and is now the largest exporter of generics in the world.1 These exports go to over 160 countries, including the United States, Australia, Russia, and nations in Asia, the Middle East, Africa, and Latin...
Data Integrity: A Vertical Journey Banner
Features
Data Integrity: A Vertical Journey
Data is an important factor that is reshaping the pharmaceutical industry and triggering significant innovation. Vertical integration of equipment can represent an optimal solution to manage the increasing flow of data efficiently, innovate the manufacturing environment, and fulfill data integrity...
Data Integrity: Beyond the Lab Banner
Features
Data Integrity: Beyond the Lab
The 2018 ISPE Quality Manufacturing Conference, held 4–6 June 2018 in Arlington, Virginia, included a well-attended session entitled “Data Integrity—Beyond the Lab,” which reaffirmed continued focus from both industry and regulators on this critical element of assuring product quality and patient...
Data Integrity in the Trenches: A Look into Quality Control Lab
Features
Data Integrity in the Trenches: A Look into Quality Control Lab
Pharmaceutical Engineering magazine’s March–April 2016 Special ReportInternational Society for Pharmaceutical Engineering. “Special Report: Data Integrity.” Pharmaceutical Engineering 36, no. 2 (March–April 2016): 39–67. highlighted the increasing importance of data integrity for companies...
Eye on the Future -banner image
Features
Eye on the Future - Janssen Expands Ireland Production Facility
Janssen is in the midst of a multimillion-dollar expansion project at the company’s Ringaskiddy, County Cork, manufacturing facility in Ireland. The 19,100-square-meter project is expected to significantly increase Janssen’s global manufacturing capacity for producing biologic medicines for...
Singapore - Biopharma’s Global Hub - ISPE Pharmaceutical Engineering Magazine
Features
Singapore - Biopharma’s Global Hub
Our May-June cover story on the rise of biopharmaceutical manufacturing in Asia noted that “Biopharmaceuticals are booming … buoyed by enhanced regulations, an influx of venture capital, a culture of innovation, and government support.”Fotheringham, S. “The Rise of Biopharmaceutical Manufacturing...
A culture of innovation banner image
Features
A Culture of Innovation
A corporate culture that supports creative thinking can help pave a road to innovation. Free people from fear and encourage them to do their best and you’ll have an environment for accomplishing great things, according to George Scangos, who has led Biogen and other pharma companies. In a recent...
Article
Features
Cm-Produced Cancer Treatment Receives FDA Approval
Eli Lilly and Company’s continuous manufacturing (CM) kits have proven to be an important manufacturing platform for the company’s oral solid dosage products (OSD). “CM is very important to Lilly as one of our proven manufacturing platforms for...
In-Line, Real-Time Powder Flow & Process Monitoring - Bottles
Features
In-Line, Real-Time Powder Flow & Process Monitoring
Innovative technology for in-line real-time powder flow monitoring based on drag force flow measurement offers great potential for efficient monitoring of powder-processing operations.
Digital Labels Revolutionize Investigational Medicinal Products (IMPs)
Features
Digital Labels Revolutionize Investigational Medicinal Products (IMPs)
Labeling is an important part of the supply chain. This is especially true for investigational medicinal products (IMPs), which must be labeled with clear expiry dates and other mandated information. IMP shelf life is notoriously difficult to quantify, however, and new findings on their stability...
transparency
Features
Blockchain: The Next Big Distruptor in Clinical Trials?
The digital revolution is driving change across all industries. With its ability to increase transparency and trust between parties, the recent innovation called blockchain has the potential to significantly disrupt the clinical trials industry.
The Fourth Industrial Revolution
Features
The Fourth Industrial Revolution
Dr. Enno de Boer says rapid, major changes are on the horizon for just about everything—including manufacturing.
Article
Features
Biosimilars: Changing the Pharmaceutical Industry
Biologics are large-molecule drugs, derived from a biological source, that treat chronic diseases such as cancer and autoimmune disorders. While small-molecule compounds continue to account for the bulk of pharmaceutical profits, biologics’ presence is...
Supply Chains Dramatic Changes Ahead
Features
Pharma Supply Chains: Dramatic Changes Ahead
Biopharmaceutical supply chains are undergoing dramatic changes that will affect the design and operation of the facilities of the future. Predominant among these is the shift away from primary care to specialty products and personalized medicine, and from large-scale production of low-value small...
Continuous Manufacturing Current Status
Features
Continuous Manufacturing Current Status
Change in the pharmaceutical industry is notoriously slow, so it wasn't surprising that many doubted continuous manufacturing (CM) would ever be adopted. But despite the skeptics, the technology is gaining substantial ground. Since 2015, four solid oral drugs produced by continuous processes have...
The Advent of Continuous Manufacturing - ISPE Pharmaceutical Engineering
Features
The Advent of Continuous Manufacturing
Spurred by pressure from governments and consumers to curb rising drug prices, pharmaceutical manufacturers are increasingly willing to look beyond traditional batch processing to cut costs and increase efficiency. One of the industry's most dramatic innovations on this front is continuous...
The Rise of Biopharmaceutical Manufacturing in Asia - ISPE Pharmaceutical Engineering
Features
The Rise of Biopharmaceutical Manufacturing in Asia
Biopharmaceuticals are booming in Asia, buoyed by enhanced regulations, an influx of venture capital, a culture of innovation, and government support. Asian pharmaceutical manufacturing has traditionally focused on generics, but things are changing.Liu, A. "AstraZeneca Allies with Alibaba and...
Article
Features
Think (Bio)Print
Great strides are being made in bioprinting, and the end result could revolutionize pharmaceutical development and testing.
In Conversation: Bringing the Outside In
Features
In Conversation: Bringing the Outside In
"When a factory is needed in the future, what could it look like, and how should we think and work differently to build it?" This is a question that Roger Connor, President, Global Manufacturing Supply, GlaxoSmithKline, considers frequently. I had the privilege of meeting him during the ISPE 2017...
Reining in Consumption for Sustainable Manufacturing
Features
Reining in Consumption for Sustainable Manufacturing
The word “sustainability” is both overused and abused: We hear about sustainable development in a sustainable economy that uses sustainable packaging for a sustainable future. But it’s an important concept, especially for the pharmaceutical industry as...
Article
Features
Embracing Innovation
ISPE has identified facilities of the future (FOF) as a priority in its strategic plan, and is paying particular attention to helping members and corporations understand the skills they will need to advance and maintain a competitive edge. These “musts”...
Francois Sallans 2017 Member of the Year
Features
Francois Salláns - 2017 Member of the Year
Maxine Seales Yonker was an active ISPE member, leader, and contributor to the industry. When she lost her battle with cancer in 2005, her memory was honored with an annual award that recognizes the same commitment to service. As he announced this...
Article
Features
Gen X, Millennial - The Mentoring Relationship, Step by Step
Mentoring is a hot topic these days. Do a quick Google search of the word “mentoring” and you’ll get some 95 million results. A narrower search, “mentoring an engineer,” will get you about 11 million results, or 12% of the first search. For even more...
Crossing Over to Large Molecules
Features
Crossing Over to Large Molecules
Improvements in genetic engineering techniques have fueled the growth of well-characterized large molecules since the 1980s. Today, revenues from the sale of biopharmaceuticals in the United States exceed $100 billion annually. Ernst & Young Global Limited (EY). "Key Dealmaking Insights," in...
Article
Features
In Good Company
The success of Novartis’s CTL019 in treating relapsed or refractory pediatric ALL, including FDA approval of the company’s biologics license application, makes it the first adoptive cell therapy to reach the market. While Novartis is also seeking...
Breakthrough for Pharma Industry & Patients
Features
Breakthrough for Pharma Industry & Patients - FDA Approved Gene Transfer Therapy
On 30 August, the US Food and Drug Administration (FDA) approved Novartis's Kymriah (tisagenlecleucel, CTL019), the first gene therapy for the treatment of pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia (ALL). Kymriah belongs to a class of drugs...
Patent Battles in the Age of Crispr
Features
Patent Battles in the Age of Crispr
The CRISPR/Cas9 system (CRISPR) developed for gene editing only a few short years ago* has already revolutionized genomic engineering, and clinical trials for targeted cancer therapies have recently commenced in China and the United States. CRISPR's power lies in its relative simplicity and...
Marriage of Pharma & Tech Yields Benefits for Patients
Features
Marriage of Pharma & Tech Yields Benefits for Patients
It is no wonder pharmaceutical companies are looking to enter new health care territory. In 2016 there were only 22 new drug approvals in the United States, returns on investment continue to fall,1 and pricing pressures continued to mount. At the same...
3D Printing & Bioprinting in Pharmaceutical Manufacturing
Features
3D Printing & Bioprinting in Pharmaceutical Manufacturing
When Aprecia Pharmaceuticals’ anti-seizure medication Spritam (levetiracetam) became the first 3D-printed* drug product to be approved by the US Food and Drug Administration (FDA) in 2016, it also became the first confirmed drug supported by a new team...
Article
Features
A Matter of Well-Being: A Profile of Anthony Maddaluna
Maintaining a robust supply of high-quality medicine is neither easy nor inexpensive. It depends on reliable processes, a secure supply chain, and a skilled workforce. Yet even when good medicines exist to treat an illness, delivery of these drugs could...
Article
Features
The Growing Influence of PIC/S in Asia Pacific
The Asia Pacific region, which comprises 24 culturally diverse countries, contains 60% of the world's population and is the fastest growing region in the world today This article describes the growing influence of Pharmaceutical Inspection Co-operation Scheme (PIC/S) in the Asia Pacific region. Of...
Compliance Challenges for Global Pharmaceutical Manufacturers
Features
Compliance Challenges for Global Pharmaceutical Manufacturers
Amid the great opportunities that flow from extending their networks of facilities around the globe, pharmaceutical manufacturers are facing compliance challenges in emerging markets—especially culturally distinct ideas about safety, risk, and quality....
What Does 2017 Hold in Store for Pharma
Features
What Does 2017 Hold in Store for Pharma?
What will be the most important industry drivers, its innovations, if any? What indeed! During the ISPE 2016 Annual Meeting Pharmaceutical Engineering caught up with a few industry leaders and asked for their perspectives. Here's what they had to say.
Article
Features
Drug Shortages Theory into Practice
After much focus at recent conferences and in publications on understanding the manufacturing- and quality-related causes of drug shortages, delegates at the 2016 ISPE Annual Meeting & Expo in Atlanta, Georgia, had the opportunity to hear from a panel of...
The Catastrophe of Drug Shortages in Pediatric Oncology
Features
The Catastrophe of Drug Shortages in Pediatric Oncology
In the 1960s, almost all children diagnosed with the most common pediatric cancer, acute lymphoblastic leukemia (ALL), were dead within 5 years. The steady and dramatic rise in survival rates since then means that today these kids have a near-90% chance...
Robin Kumoluyi
Features
The New Face of Leadership: Robin Kumoluyi
Three generations ago, a university degree granted admission to a well-paying 40-year career at a single company whose end point, often as not, was an engraved watch. Today, things are different. According to the US Bureau of Labor Statistics, the...
Transitioning To Multicolumn Chromatography
Features
Challenges & Results: Moving to Multicolumn Chromatography
Although pharmaceutical manufacturing is traditionally a change-averse industry, the benefits of continuous processing demonstrated in other industries are beginning to drive interest in its application to bioprocessing. This article reports on...